Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANGNNYSEAMERICAN:PFNXNASDAQ:SNSENASDAQ:TERNNASDAQ:TH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANGNAngion Biomedica$6.48$0.46▼$2.04$30.11M0.686,718 shs224,800 shsPFNXPfenex$12.75$12.75$5.26▼$14.00$437.29MN/A503,865 shsN/ASNSESensei Biotherapeutics$9.08-2.1%$7.28$5.00▼$17.40$11.68M0.2745,504 shs5,809 shsTERNTerns Pharmaceuticals$4.23-0.7%$3.44$1.87▼$11.40$372.05M-0.111.47 million shs263,302 shsTHTarget Hospitality$7.34+1.9%$7.08$4.00▼$11.10$715.43M1.83549,584 shs317,458 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANGNAngion Biomedica0.00%0.00%0.00%0.00%0.00%PFNXPfenex0.00%0.00%0.00%0.00%0.00%SNSESensei Biotherapeutics-2.05%+8.42%+34.21%+57.17%-27.07%TERNTerns Pharmaceuticals-0.70%+5.75%+21.20%+101.43%-38.34%THTarget Hospitality+1.88%+1.73%+1.45%+11.98%-15.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANGNAngion BiomedicaN/AN/AN/AN/AN/AN/AN/AN/APFNXPfenexN/AN/AN/AN/AN/AN/AN/AN/ASNSESensei Biotherapeutics4.2191 of 5 stars3.75.00.04.80.01.71.3TERNTerns Pharmaceuticals4.0773 of 5 stars3.31.00.04.13.33.30.0THTarget Hospitality2.8838 of 5 stars3.43.00.00.01.71.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANGNAngion Biomedica 0.00N/AN/AN/APFNXPfenex 0.00N/AN/AN/ASNSESensei Biotherapeutics 3.33Buy$90.00891.74% UpsideTERNTerns Pharmaceuticals 2.60Moderate Buy$15.63269.39% UpsideTHTarget Hospitality 2.75Moderate Buy$11.2553.37% UpsideCurrent Analyst Ratings BreakdownLatest ANGN, TH, PFNX, TERN, and SNSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$100.005/13/2025TERNTerns PharmaceuticalsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$26.00 ➝ $15.005/1/2025SNSESensei BiotherapeuticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/21/2025TERNTerns PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$20.00 ➝ $20.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANGNAngion Biomedica$2.30M0.00N/AN/A$1.32 per share0.00PFNXPfenexN/AN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/A$30.52 per shareN/ATERNTerns PharmaceuticalsN/AN/AN/AN/A$4.07 per shareN/ATHTarget Hospitality$386.27M1.89$1.51 per share4.85$4.26 per share1.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANGNAngion Biomedica-$38.81MN/A0.00N/AN/AN/A-47.53%-40.55%N/APFNXPfenexN/AN/A0.00∞N/AN/AN/AN/AN/ASNSESensei Biotherapeutics-$30.16M-$23.00N/AN/AN/AN/A-66.72%-57.10%8/5/2025 (Estimated)TERNTerns Pharmaceuticals-$88.85M-$1.09N/AN/AN/AN/A-28.81%-27.55%8/4/2025 (Estimated)THTarget Hospitality$71.26M$0.4317.0620.38N/A12.71%11.34%6.94%8/6/2025 (Estimated)Latest ANGN, TH, PFNX, TERN, and SNSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025THTarget Hospitality-$0.02-$0.05-$0.03-$0.07$65.37 million$69.90 million5/8/2025Q1 2025TERNTerns Pharmaceuticals-$0.29-$0.26+$0.03-$0.26N/AN/A5/6/2025Q1 2025SNSESensei Biotherapeutics-$4.20-$5.40-$1.20-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANGNAngion BiomedicaN/AN/AN/AN/AN/APFNXPfenexN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ATHTarget HospitalityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANGNAngion BiomedicaN/A20.0020.00PFNXPfenexN/AN/AN/ASNSESensei BiotherapeuticsN/A6.826.82TERNTerns PharmaceuticalsN/A30.8930.89THTarget Hospitality0.101.971.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANGNAngion Biomedica17.00%PFNXPfenexN/ASNSESensei Biotherapeutics10.50%TERNTerns Pharmaceuticals98.26%THTarget Hospitality32.40%Insider OwnershipCompanyInsider OwnershipANGNAngion Biomedica19.70%PFNXPfenexN/ASNSESensei Biotherapeutics23.20%TERNTerns Pharmaceuticals1.50%THTarget Hospitality68.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANGNAngion Biomedica330.11 million24.18 millionNot OptionablePFNXPfenex7134.30 millionN/ANot OptionableSNSESensei Biotherapeutics401.26 million968,000Not OptionableTERNTerns Pharmaceuticals4087.34 million86.03 millionNot OptionableTHTarget Hospitality82099.36 million31.80 millionNot OptionableANGN, TH, PFNX, TERN, and SNSE HeadlinesRecent News About These CompaniesTarget Hospitality (TH) and Its Rivals Head-To-Head Survey1 hour ago | americanbankingnews.comTarget Hospitality’s Q1 Earnings Call: Our Top 5 Analyst QuestionsJuly 1 at 12:28 PM | msn.comTarget Hospitality (TH) & The Competition Head-To-Head ContrastJune 30, 2025 | americanbankingnews.comContrasting Target Hospitality (TH) & Its CompetitorsJune 29, 2025 | americanbankingnews.comTH Target Hospitality Corp. - Seeking AlphaJune 28, 2025 | seekingalpha.comShort Interest in Target Hospitality Corp. (NASDAQ:TH) Expands By 23.9%June 18, 2025 | marketbeat.com50,000 Shares in Target Hospitality Corp. (NASDAQ:TH) Acquired by Fortitude Advisory Group L.L.C.June 17, 2025 | marketbeat.comBank of America Corp DE Sells 99,159 Shares of Target Hospitality Corp. (NASDAQ:TH)June 14, 2025 | marketbeat.comTarget Hospitality (NASDAQ:TH) Upgraded at Wall Street ZenJune 14, 2025 | marketbeat.comTwo Sigma Investments LP Has $1.25 Million Holdings in Target Hospitality Corp. (NASDAQ:TH)June 5, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 78,926 Shares of Target Hospitality Corp. (NASDAQ:TH)June 4, 2025 | marketbeat.comTH Q1 Earnings Call: Revenue Miss and Government Contract Shifts Shape 2025 OutlookMay 30, 2025 | msn.comAnalysts Offer Insights on Industrial Goods Companies: Target Hospitality (TH), Paccar (PCAR) and Carrier Global (CARR)May 22, 2025 | theglobeandmail.comTarget Hospitality Announces Seat on $4 Billion Multi-Year U.S. Government Strategic Sourcing VehicleMay 21, 2025 | prnewswire.comTarget Hospitality Corp. (NASDAQ:TH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | insidermonkey.comTarget Hospitality Corp. (NASDAQ:TH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | msn.comTarget Hospitality Corp. (TH) Q1 2025 Earnings Call TranscriptMay 19, 2025 | seekingalpha.comTarget Hospitality (NASDAQ:TH) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds ExpectationsMay 19, 2025 | msn.comTarget Hospitality (TH) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 19, 2025 | zacks.comTarget Hospitality (TH) Reports Q1 Loss, Tops Revenue EstimatesMay 19, 2025 | zacks.comTarget Hospitality Reports First Quarter 2025 Results with Continued Focus on Pursuing Strong Strategic Growth PipelineMay 19, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI Spending3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeANGN, TH, PFNX, TERN, and SNSE Company DescriptionsAngion Biomedica NASDAQ:ANGNAngion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.Pfenex NYSEAMERICAN:PFNX$12.75 0.00 (0.00%) As of 10/1/2020Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.Sensei Biotherapeutics NASDAQ:SNSE$9.14 -0.13 (-1.36%) As of 07/3/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.Terns Pharmaceuticals NASDAQ:TERN$4.23 -0.03 (-0.70%) As of 07/3/2025 02:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.Target Hospitality NASDAQ:TH$7.34 +0.14 (+1.88%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Target Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
